What's in Luxurgery's pipeline?

Luxurgery has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Luxurgery's portfolio?

Top competitors by shared drug class: Charitable Union for the Research and Education of Peyronie's Disease, DMR Research, PLLC, Hospital for Special Surgery, New York, Indiana Hand to Shoulder Center.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/luxurgery.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-15 · How we verify

Luxurgery — Portfolio Competitive Intelligence Brief

Luxurgery pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Collagenase Clostridium Histolyticum-Aaes	Collagenase Clostridium Histolyticum-Aaes	marketed	Collagenase enzyme	Collagen types I and III	Dermatology / Rheumatology

Therapeutic area mix

Dermatology / Rheumatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Charitable Union for the Research and Education of Peyronie's Disease · 1 shared drug class
DMR Research, PLLC · 1 shared drug class
Hospital for Special Surgery, New York · 1 shared drug class
Indiana Hand to Shoulder Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Luxurgery:

Cite this brief

Drug Landscape (2026). Luxurgery — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/luxurgery. Accessed 2026-05-15.